Isildinha Reis

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Radiotherapy 76%
3. Prostatic Neoplasms 67%
4. Survival 61%
5. Docetaxel 50%
6. Progression-Free Survival 46%
7. Neoplasms 45%
8. Radiation 40%
9. Lymphoma 40%
10. Drug Therapy 38%
11. Squamous Cell Carcinoma of Head and Neck 34%
12. Therapeutics 32%
13. Arsenic Trioxide 31%
14. Recurrence 30%
15. Estrogen Receptors 29%
16. Prostate 28%
17. Methylation 27%
18. Odds Ratio 27%
19. 130-nm albumin-bound paclitaxel 27%
20. Neoadjuvant Therapy 26%
21. Cystectomy 26%
22. Mastectomy 26%
23. Multiparametric Magnetic Resonance Imaging 26%
24. Oropharyngeal Neoplasms 23%
25. Breast 23%
26. Survival Analysis 22%
27. Robotics 21%
28. Population 21%
29. Second Primary Neoplasms 21%
30. Head and Neck Neoplasms 21%
31. Biomarkers 20%
32. European Continental Ancestry Group 20%
33. Confidence Intervals 20%
34. Inflammatory Breast Neoplasms 19%
35. Cisplatin 17%
36. Epidemiology 17%
37. Immunohistochemistry 17%
38. Cell-Free Nucleic Acids 17%
39. Tadalafil 17%
40. Pancreatic Neoplasms 17%
41. Trastuzumab 16%
42. Biopsy 16%
43. gemcitabine 16%
44. Prostatectomy 16%
45. Thoracic Wall 16%
46. Neoplasm Grading 15%
47. Mouthwashes 15%
48. Mantle-Cell Lymphoma 15%